ResMed (RMD) Tops Q2 EPS by 22c, Beats on Revenues
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $188.45 -0.1%
Revenue Growth %: +13.1%
Financial Fact:
Total other income, net: -1.22M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +13.1%
Financial Fact:
Total other income, net: -1.22M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q2 EPS of $1.00, $0.22 better than the analyst estimate of $0.78. Revenue for the quarter came in at $601 million versus the consensus estimate of $580.32 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- Alphabet slides over 6% as AI brain drain and SpaceX slump converge
- Sun Communities names Ileana McAlary as general counsel and EVP
Create E-mail Alert Related Categories
Corporate News, Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
